Last reviewed · How we verify
NCT06614621
A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer
Phase 2 trial testing Adebrelimab +Etoposide+Platinum-based drugs in Extensive-Stage Small Cell Lung Cancer in 43 participants. Not yet recruiting.
1 December 2027
Quick facts
| Lead sponsor | Fujian Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 43 |
| Start date | 1 February 2025 |
| Primary completion | 1 December 2027 |
| Estimated completion | 1 December 2028 |
Drugs / interventions tested
- Adebrelimab +Etoposide+Platinum-based drugs — full drug profile →
- Maintenance treatment period: — full drug profile →
Conditions studied
- Extensive-Stage Small Cell Lung Cancer — all drugs for Extensive-Stage Small Cell Lung Cancer →
Sponsor
Fujian Cancer Hospital
Who can join
Adults 18 to 75, any sex, with Extensive-Stage Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A study of adebelimab in combination with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Adebrelimab in Small Cell Lung Cancer: From Current Advances to Emerging Combination Strategy and Challenge.
Yang H, Yang L, Liu Y, Wang L. · · 2025 · PMID 40475251 · DOI 10.2147/btt.s500470
Verify or expand the search:
- PubMed search for NCT06614621
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Extensive-Stage Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06646276 — A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination W · Phase 3 · recruiting
Other Fujian Cancer Hospital trials
Trials by the same sponsor.
- NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
- NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
- NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06614621 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
- Last refreshed: 26 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06614621.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing